

15 April 2024

## Botanix included in the All Ordinaries Index

### Key highlights

- **Botanix Pharmaceuticals has been included in the ASX All Ordinaries Index**
- **Based on its strong share performance over the last 12 months, Botanix has joined the ranks of the index, which comprises the 500 largest companies listed on the ASX**
- **The performance of Botanix shares has been driven by interest in the Company's treatment for excessive underarm sweating that is expected to receive approval from the US FDA in late June**

**Philadelphia and Phoenix US, 15 April 2024:** Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX:BOT, "Botanix" or "the Company"), is honoured to announce the Company's inclusion in the ASX All Ordinaries Index. Botanix joins the ranks of the index, based on its strong performance over the last 12 months.

The performance of Botanix shares has been driven by interest in the Company's Sofpironium Bromide gel, *Sofdra*<sup>™</sup>, which is a topical treatment for excessive underarm sweating that is expected to receive approval from the US FDA in late June. Botanix launch preparations are well underway.

**Botanix Chief Executive Officer, Howie McKibbon, commented:** *"We are humbled to acknowledge the confidence investors have shown in our company, as exemplified by our inclusion in the ASX All Ordinaries Index."*

*"The generous investments made in Botanix well position us for the successful launch of Sofdra, which is expected to follow shortly after its anticipated approval in late June 2024."*

This ASX announcement is authorised for release by the Board.

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis through FDA approval. FDA accepted the resubmission of the NDA for *Sofdra* in January 2024 as a complete response and confirmed a target approval timing for late June 2024. *Sofdra* is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical development for range of other dermatology conditions. To learn more please visit: <http://www.botanixpharma.com/>

**For more information, please contact:**

**General enquiries**

Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6555 2945  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

**Investor enquiries**

Hannah Howlett  
WE Communications  
P: +61 450 648 064  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

**Media enquiries**

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

**Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for its product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of *Sofdra* and the market for *Sofdra*. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. Likewise, comments from the FDA do not reflect a final decision on the information reviewed as part of any NDA submission and should not be construed to do so. These comments are preliminary and may be subject to change as FDA finalizes its review of any NDA and FDA may also identify other information that must be provided before any application can be approved. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.